Vascular Effects of Nutritional Supplementation With a Standardised Preparation of Tomato Extract (Ateronon) in Vivo in Man
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 72
- 试验地点
- 2
- 主要终点
- Forearm blood flow ratio and/or absolute flow in the infused arm (and % change), as measured by venous occlusion plethysmography, in response to intra-arterial acetylcholine infusion.
研究概览
简要总结
Does tomato extract improve blood vessel function in healthy people and people with cardiovascular disease?
Atherosclerosis ('furring' of the arteries) affects the functioning of blood vessels, narrowing and eventually blocking them, causing conditions like heart attack and stroke. The Mediterranean diet, which is rich in tomatoes and tomato-based products, has been shown to be associated with a reduced risk of blood vessel damage. In this double blind, placebo-controlled randomised study, the investigators will investigate whether a food supplement containing a standardised extract of tomato improves blood vessel function in both healthy people (aged 40-80), and people with a history of cardiovascular disease. The food supplement is on sale to the public, and the investigators are testing the standard dose. Approximately 72 people will take part at the Clinical Pharmacology Unit at the ACCI Building, Cambridge University Hospitals NHS Trust.
After they have passed screening tests, participants will be allocated by chance to receive either the tomato extract product (Ateronon), or a matching placebo (a dummy capsule with no active ingredients), which they will take once a day for 8 weeks. At the beginning and end of the treatment period, the investigators will test blood vessel stiffness using an ECG machine and external probe. The investigators will also measure forearm blood flow, which involves infusing 3 separate agents that affect how the lining of the blood vessel wall works, and helps to assess whether this is affected by the study treatment. Blood tests will also be used to look at how the food supplement is working and its effects on cholesterol and markers of inflammation. Including the screening period, and a follow-up telephone call two weeks after the end of treatment, participants will be in the study for 14 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 80 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged between 30 and 80 years
- •Non-smoking
排除标准
- •Hypertension or other cardiovascular disease
- •Significant renal, respiratory or neurological disease
- •Diabetes mellitus
- •BMI>32, BMI<18
- •Use of vasoactive medication
- •Use of heparin or warfarin
- •Allergy/intolerance to study substance ingredients
- •STABLE CARDIOVASCULAR DISEASE GROUP
- •Inclusion Criteria:
- •Aged between 40 and 80 years
- •Previous ischaemic heart disease (any of previous myocardial infarction, coronary stent, angina), transient ischaemic attack or stroke disease or peripheral vascular disease
- •If taking a statin, dose must have been stable over preceding 2 months
- •Exclusion Criteria:
- •Uncontrolled hypertension
- •Use of heparin or warfarin
- •Allergy/intolerance to study substance ingredients
结局指标
主要结局
Forearm blood flow ratio and/or absolute flow in the infused arm (and % change), as measured by venous occlusion plethysmography, in response to intra-arterial acetylcholine infusion.
时间窗: 8 weeks
次要结局
- Safety and tolerability parameters, including physical examination, blood pressure, heart rate, 12-lead electrocardiograms (ECGs), clinical laboratory tests and adverse event reporting.(8 weeks)
- Forearm blood flow ratio and/or absolute flow in the infused arm (& % change), as measured by venous occlusion plethysmography, in response to intra-arterial sodium nitroprusside and L-NMMA infusion.(8 weeks)
- Pulse wave velocity measured between carotid and femoral artery.(8 weeks)
- Analysis of Lipoprotein oxidation/circulating markers.(8 weeks)
- Evaluation of pulse wave velocity and pulse wave analysis(8 weeks)
研究者
Joseph Cheriyan, MD
Consultant Physician
Cambridge University Hospitals NHS Foundation Trust
